Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chimerigen
CD279 [PD-1] (human) (rec.)
Product Details | |
---|---|
Synonyms | PD-1; Programmed Cell Death Protein 1 |
Product Type | Protein |
Properties | |
Source/Host | HEK 293 cells |
Sequence |
The extracellular domain of human CD279 [PD-1] (aa 25-167) is untagged. |
Crossreactivity | Human |
Biological Activity |
Measured by its binding ability in a functional ELISA. |
MW | ~30kDa (SDS-PAGE) |
Purity | ≥95% (SDS-PAGE) |
Endotoxin Content | <1EU/mg protein (LAL test; Lonza). |
Reconstitution |
Reconstitute 50µg vial with 100 µl sterile water to a concentration of 0.5mg/ml. Add 1X PBS to the desired protein concentration. |
Formulation | Lyophilized from 0.2μm-filtered solution in PBS. |
Other Product Data |
NCBI reference NP_005009.2: CD279 (human) |
Declaration | Manufactured by Chimerigen. |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice |
Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. PBS containing at least 0.1% BSA should be used for further dilutions. |
Use/Stability |
Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
CD279 (Programmed Cell Death Protein 1; PD-1) is a type I transmembrane protein belonging to the CD28/CTLA-4 family of immunoreceptors that mediate signals for regulating immune responses. Members of the CD28/CTLA-4 family have been shown to either promote T cell activation (CD28 and ICOS) or downregulate T cell activation (CTLA-4 and PD-1). CD279 is expressed on activated T cells, B cells, myeloid cells and on a subset of thymocytes. In vitro, ligation of CD279 inhibits TCR-mediated T cell proliferation and production of IL-1, IL-4, IL-10 and IFN-γ. In addition, CD279 ligation also inhibits BCR mediated signaling. CD279 deficient mice have a defect in peripheral tolerance and spontaneously develop autoimmune diseases.